Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ernesto Rossi, Ilaria Grazia Zizzari, Alessandra Di Filippo, Anna Acampora, Monica Maria Pagliara, Maria Grazia Sammarco, Maurizio Simmaco, Luana Lionetto, Andrea Botticelli, Emilio Bria, Paolo Marchetti, Maria Antonietta Blasi, Giampaolo Tortora, Giovanni Schinzari & Marianna Nuti. (2022) Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. Human Vaccines & Immunotherapeutics 18:3.
Read now
Read now
Ernesto Rossi, Giovanni Schinzari, Brigida Anna Maiorano, Giulia Indellicati, Alessandro Di Stefani, Monica Maria Pagliara, Simona Maria Fragomeni, Erika Valentina De Luca, Maria Grazia Sammarco, Giorgia Garganese, Jacopo Galli, Maria Antonietta Blasi, Gaetano Paludetti, Giovanni Scambia, Ketty Peris & Giampaolo Tortora. (2021) Efficacy of immune checkpoint inhibitors in different types of melanoma. Human Vaccines & Immunotherapeutics 17:1, pages 4-13.
Read now
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now
Read now
Manni Wang, Xuelei Ma, Linghong Guo & Fan Xia. (2017) Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Design, Development and Therapy 11, pages 2851-2860.
Read now
Read now
Pol Specenier. (2017) Pembrolizumab use for the treatment of advanced melanoma. Expert Opinion on Biological Therapy 17:6, pages 765-780.
Read now
Read now
Articles from other publishers (63)
James P. Pham, Lawrence On, Luke Ardolino, Joshua Hurwitz, Helene Salaun, Hao-Wen Sim & Anthony M. Joshua. (2023) Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Research 33:4, pages 316-325.
Crossref
Crossref
Wei Huang, Fan Yang, Yichi Zhang, Qianqi Fang, Yitao Lai & Yuqing Lan. (2023) A Newly Established Cuproptosis-Related Gene Signature for Predicting Prognosis and Immune Infiltration in Uveal Melanoma. International Journal of Molecular Sciences 24:14, pages 11358.
Crossref
Crossref
T. M. L. Tong, M. C. Burgmans, F. M. Speetjens, A. R. van Erkel, R. W. van der Meer, C. S. P. van Rijswijk, M. A. Jonker-Bos, C. F. M. Roozen, M. Sporrel-Blokland, J. Lutjeboer, E. L. van Persijn van Meerten, C. H. Martini, R. W. M. Zoethout, F. G. J. Tijl, C. U. Blank & E. Kapiteijn. (2023) Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. CardioVascular and Interventional Radiology 46:3, pages 350-359.
Crossref
Crossref
Dharmadev B. Trivedi, Natasha Aldulaimi, Ioannis Karydis, Matthew Wheater, Sachin Modi, Brian Stedman, Dimitrios Karavias, John Primrose, Neil Pearce & Arjun S. Takhar. (2022) Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature. Melanoma Research 33:1, pages 71-79.
Crossref
Crossref
Richard D. Carvajal, Joseph J. Sacco, Martine J. Jager, David J. Eschelman, Roger Olofsson Bagge, J. William Harbour, Nicholas D. Chieng, Sapna P. Patel, Anthony M. Joshua & Sophie Piperno-Neumann. (2023) Advances in the clinical management of uveal melanoma. Nature Reviews Clinical Oncology 20:2, pages 99-115.
Crossref
Crossref
Bogdan Marian Caraban, Elena Matei, Georgeta Camelia Cozaru, Mariana Aşchie, Mariana Deacu, Manuela Enciu, Gabriela Izabela Bălţătescu, Anca Chisoi, Nicolae Dobrin, Lucian Petcu, Emma Gheorghe, Laurențiu-Tony Hangan, Mihai Cătălin Roșu, Cristian Ionuț Orasanu & Antonela-Anca Nicolau. (2023) PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. Journal of Personalized Medicine 13:2, pages 221.
Crossref
Crossref
Luka de Vos, Tzaitel Maria Carrillo Cano, Romina Zarbl, Niklas Klümper, Damian Johannes Ralser, Alina Franzen, Emmanuelle Herr, Jennis Gabrielpillai, Timo Jakob Vogt, Jörn Dietrich, Sebastian Strieth, Jennifer Landsberg & Dimo Dietrich. (2022) CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma. Journal of Immunotherapy 45:7, pages 324-334.
Crossref
Crossref
Elina S. Rantala, Micaela M. Hernberg, Sophie Piperno-Neumann, Hans E. Grossniklaus & Tero T. Kivelä. (2022) Metastatic uveal melanoma: The final frontier. Progress in Retinal and Eye Research 90, pages 101041.
Crossref
Crossref
Yongchao Zhang, Bozhi Liu, Sergei Kotenko & Wei Li. (2022) Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Medicine 101:32, pages e29536.
Crossref
Crossref
Pui Ying Chan, Melissa M. Phillips, Stephen Ellis, Amanda Johnston, Xiaoxing Feng, Amit Arora, Gordon Hay, Victoria M. L. Cohen, Mandeep S. Sagoo, John S. Bomalaski, Michael T. Sheaff & Peter W. Szlosarek. (2022)
A Phase 1 study of
ADI‐PEG20
(pegargiminase) combined with cisplatin and pemetrexed in
ASS1‐negative
metastatic uveal melanoma
. Pigment Cell & Melanoma Research 35:4, pages 461-470.
Crossref
Crossref
Yihang Fu, Wei Xiao & Yuxiang Mao. (2022) Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers 14:13, pages 3094.
Crossref
Crossref
Celine A Fadel, Swathi Kanakamedala, Shivang U Danak & Andrew T Johnson. (2022) A Rare Case of Metastatic Uveal Melanoma Responding to Immunotherapy. Cureus.
Crossref
Crossref
Xiaochen Ma, Sejie Yu, Bin Zhao, Wei Bai, Yubo Cui, Jinglan Ni, Qinghua Lyu & Jun Zhao. (2022) Development and Validation of a Novel Ferroptosis-Related LncRNA Signature for Predicting Prognosis and the Immune Landscape Features in Uveal Melanoma. Frontiers in Immunology 13.
Crossref
Crossref
Sachin Modi, Tom Gibson, Ganesh Vigneswaran, Shian Patel, Matthew Wheater, Ioannis Karydis, Sanjay Gupta, Arjun Takhar, Neil Pearce, Christian Ottensmeier & Brian Stedman. (2022) Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Research 32:2, pages 103-111.
Crossref
Crossref
Amritlal Mandal, Mathews Valuparampil Varghese & Joel James. 2022. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects
3773
3792
.
Amritlal Mandal, Mathews Valuparampil Varghese & Joel James. 2021. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects
1
20
.
V. V. Saevets, A. Y. Shamanova & D. M. Rostovcev. (2021) Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms. Ural Medical Journal 20:4, pages 78-84.
Crossref
Crossref
Janney Z. Wang, Vivian Lin, Elsa Toumi, Ke Wang, Hong Zhu, R. Max Conway, Michele C. Madigan, Michael Murray, Svetlana Cherepanoff, Fanfan Zhou & Wenying Shu. (2021) Development of new therapeutic options for the treatment of uveal melanoma. The FEBS Journal 288:21, pages 6226-6249.
Crossref
Crossref
A. Y. Shamanova, E. L. Kazachkov, I. Е. Panova, A. V. Vazhenin, Т. N. Shamaeva & Е. A. Alymov. (2021) Features of the lymphocytic microenvironment in metastatic uveal melanoma. Ural Medical Journal 20:2, pages 36-42.
Crossref
Crossref
Rumana N. Hussain, Sarah E. Coupland, Helen Kalirai, Azzam F. G. Taktak, Antonio Eleuteri, Bertil E. Damato, Carl Groenewald & Heinrich Heimann. (2021) Small High-Risk Uveal Melanomas Have a Lower Mortality Rate. Cancers 13:9, pages 2267.
Crossref
Crossref
Richard Carvajal & Rohan Maniar. (2021) Extracutaneous Melanoma. Hematology/Oncology Clinics of North America 35:1, pages 85-98.
Crossref
Crossref
Jun Xu, Jianguo Zhao, Jianfang Wang, Caiping Sun & Xiaoling Zhu. (2021) Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy. Medicine 100:14, pages e25318.
Crossref
Crossref
E. Livingstone, A. Zaremba, S. Horn, S. Ugurel, B. Casalini, M. Schlaak, J.C. Hassel, R. Herbst, J.S. Utikal, B. Weide, R. Gutzmer, F. Meier, C. Koelsche, E. Hadaschik, A. Sucker, H. Reis, S. Merkelbach‐Bruse, M. Siewert, F. Sahm, A. Deimling, I. Cosgarea, L. Zimmer, D. Schadendorf, B. Schilling & K.G. Griewank. (2020)
GNAQ
and
GNA
11
mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma
. British Journal of Dermatology 183:5, pages 928-939.
Crossref
Crossref
Cristina Rodriguez-Vidal, Daniel Fernandez-Diaz, Beatriz Fernandez-Marta, Nerea Lago-Baameiro, María Pardo, Paula Silva, Laura Paniagua, María José Blanco-Teijeiro, Antonio Piñeiro & Manuel Bande. (2020) Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers 12:9, pages 2557.
Crossref
Crossref
Snježana Kaštelan, Antonela Gverović Antunica, Lidija Beketić Oresković, Goran Pelčić, Ema Kasun & Koraljka Hat. (2020) Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives. Current Medicinal Chemistry 27:8, pages 1350-1366.
Crossref
Crossref
Kenjiro Namikawa, Akira Takahashi, Taisuke Mori, Arata Tsutsumida, Shigenobu Suzuki, Noriko Motoi, Shunichi Jinnai, Yuta Kage, Haruki Mizuta, Yusuke Muto, Eiji Nakano & Naoya Yamazaki. (2020) Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study. Melanoma Research 30:1, pages 76-84.
Crossref
Crossref
Anja Wessely, Theresa Steeb, Michael Erdmann, Lucie Heinzerling, Julio Vera, Max Schlaak, Carola Berking & Markus Vincent Heppt. (2020) The Role of Immune Checkpoint Blockade in Uveal Melanoma. International Journal of Molecular Sciences 21:3, pages 879.
Crossref
Crossref
Yanina Jeanne Leona Jansen, Teofila Seremet & Bart Neyns. (2020) Pembrolizumab for the treatment of uveal melanoma: A case series. Rare Tumors 12, pages 203636132097198.
Crossref
Crossref
Suthee Rapisuwon, Yong Qin, Jason Roszik, Fernando Carapeto, Sapna Patel & Richard D. Carvajal. 2020. Cutaneous Melanoma. Cutaneous Melanoma
1301
1335
.
Markus V. Heppt, Teresa Amaral, Katharina C. Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meissner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai-Martin Thoms, Lisa Zimmer, Thomas K. Eigentler, Michael C. Kirchberger, Henner M. Stege, Friedegund Meier, Max Schlaak & Carola Berking. (2019) Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Elina S. Rantala, Micaela Hernberg & Tero T. Kivelä. (2019) Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Research 29:6, pages 561-568.
Crossref
Crossref
Bol, Ellebaek, Hoejberg, Bagger, Larsen, Klausen, Køhler, Schmidt, Bastholt, Kiilgaard, Donia & Svane. (2019) Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers 11:10, pages 1489.
Crossref
Crossref
Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Vincenzo Fiorentino, Gianluigi Petrone, Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Marianna Nuti & Giampaolo Tortora. (2019) Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. Cancers 11:8, pages 1055.
Crossref
Crossref
Manuel Rodrigues, Leanne de Koning, Sarah Coupland, Aart Jochemsen, Richard Marais, Marc-Henri Stern, André Valente, Raymond Barnhill, Nathalie Cassoux, Andrew Evans, Iain Galloway, Martine Jager, Ellen Kapiteijn, Bozena Romanowska-Dixon, Bettina Ryll, Sergio Roman-Roman & Sophie Piperno-Neumann. (2019) So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020. Cancers 11:7, pages 1032.
Crossref
Crossref
Ernesto Rossi, Monica Maria Pagliara, Daniela Orteschi, Tommaso Dosa, Maria Grazia Sammarco, Carmela Grazia Caputo, Gianluigi Petrone, Guido Rindi, Marcella Zollino, Maria Antonietta Blasi, Alessandra Cassano, Emilio Bria, Giampaolo Tortora & Giovanni Schinzari. (2019) Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunology, Immunotherapy 68:7, pages 1179-1185.
Crossref
Crossref
Sara Violanti, Ilaria Bononi, Carla Gallenga, Fernanda Martini, Mauro Tognon & Paolo Perri. (2019) New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. Cancers 11:5, pages 694.
Crossref
Crossref
Shiqiong Xu, Hong Yu, Guohui Fu, Xianqun Fan & Renbing Jia. (2018) Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients. Acta Ophthalmologica 97:3, pages e390-e396.
Crossref
Crossref
Chen Liang, Lanya Peng, Shaoxue Zeng, Qing Zhao, Linqiao Tang, Xiaoshuang Jiang, JunJun Zhang, Naihong Yan & YingYing Chen. (2019) Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma. Experimental Eye Research 181, pages 112-119.
Crossref
Crossref
V. Kakkassery, A. M. Jünemann, B. O. Scheef, S. Grisanti & L. M. Heindl. (2019) Neue molekularpathologische Ansätze bei malignen IristumorenNew molecular pathological strategies for malignant iris tumors. Der Ophthalmologe 116:4, pages 324-331.
Crossref
Crossref
Fausto Petrelli, Raffaele Ardito, Barbara Merelli, Veronica Lonati, Mary Cabiddu, Silvia Seghezzi, Sandro Barni & Antonio Ghidini. (2019) Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Melanoma Research 29:1, pages 1-12.
Crossref
Crossref
Eric Fountain, Roland Bassett, Suzanne Cain, Liberty Posada, Dan Gombos, Patrick Hwu, Agop Bedikian & Sapna Patel. (2019) Adjuvant Ipilimumab in High-Risk Uveal Melanoma. Cancers 11:2, pages 152.
Crossref
Crossref
Kenjiro Namikawa & Naoya Yamazaki. (2019) Targeted Therapy and Immunotherapy for Melanoma in Japan. Current Treatment Options in Oncology 20:1.
Crossref
Crossref
Suthee Rapisuwon, Yong Qin, Jason Roszik, Fernando Carapeto, Sapna Patel & Richard D. Carvajal. 2019. Cutaneous Melanoma. Cutaneous Melanoma
1
37
.
Muhammad Zubair Afzal, Rodwell Mabaera & Keisuke Shirai. (2018) Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Katy K. Tsai, Kathryn B. Bollin & Sapna P. Patel. (2018) Obstacles to improving outcomes in the treatment of uveal melanoma. Cancer 124:13, pages 2693-2703.
Crossref
Crossref
Lauren A. Dalvin, Carol L. Shields, Marlana OrloffTakami SatoJerry A. Shields. (2018) CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina 38:6, pages 1063-1078.
Crossref
Crossref
Manuel Rodrigues, Lenha Mobuchon, Alexandre Houy, Alice Fiévet, Sophie Gardrat, Raymond L. Barnhill, Tatiana Popova, Vincent Servois, Aurore Rampanou, Aurore Mouton, Stéphane Dayot, Virginie Raynal, Michèle Galut, Marc Putterman, Sarah Tick, Nathalie Cassoux, Sergio Roman-Roman, François-Clément Bidard, Olivier Lantz, Pascale Mariani, Sophie Piperno-Neumann & Marc-Henri Stern. (2018) Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nature Communications 9:1.
Crossref
Crossref
Ioannis Karydis, Alexandra Gangi, Matthew J. Wheater, Junsung Choi, Iain Wilson, Kerry Thomas, Neil Pearce, Arjun Takhar, Sanjay Gupta, Danielle Hardman, Sean Sileno, Brian Stedman, Jonathan S. Zager & Christian Ottensmeier. (2017) Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Journal of Surgical Oncology 117:6, pages 1170-1178.
Crossref
Crossref
Riccardo Marconcini, Francesco Spagnolo, Luigia Stefania Stucci, Simone Ribero, Elena Marra, Francesco De Rosa, Virginia Picasso, Lorenza Di Guardo, Carolina Cimminiello, Stefano Cavalieri, Laura Orgiano, Enrica Tanda, Laura Spano, Alfredo Falcone & Paola Queirolo. (2018) Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget 9:15, pages 12452-12470.
Crossref
Crossref
Jessica Yang, Daniel K. Manson, Brian P. Marr & Richard D. Carvajal. (2018) Treatment of uveal melanoma: where are we now?. Therapeutic Advances in Medical Oncology 10, pages 175883401875717.
Crossref
Crossref
Giovanni Schinzari, Ernesto Rossi, Alessandra Cassano, Vincenzo Dadduzio, Michela Quirino, Monica Pagliara, Maria A. Blasi & Carlo Barone. (2017) Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Melanoma Research 27:6, pages 591-595.
Crossref
Crossref
Eddie Gibson, Ian Koblbauer, Najida Begum, George Dranitsaris, Danny Liew, Phil McEwan, Amir Abbas Tahami Monfared, Yong Yuan, Ariadna Juarez-Garcia, David Tyas & Michael Lees. (2017) Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. PharmacoEconomics 35:12, pages 1257-1270.
Crossref
Crossref
Markus V. Heppt, Theresa Steeb, Justin Gabriel Schlager, Stefanie Rosumeck, Corinna Dressler, Thomas Ruzicka, Alexander Nast & Carola Berking. (2017) Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. Cancer Treatment Reviews 60, pages 44-52.
Crossref
Crossref
Beatriz Álvarez-Rodríguez, Alfonso Latorre, Christian Posch & Álvaro Somoza. (2017) Recent advances in uveal melanoma treatment. Medicinal Research Reviews 37:6, pages 1350-1372.
Crossref
Crossref
Genevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, Valliammai Muthappan, Jessica Esandrio, Sneha Berry, Haiying Xu, Aleksandra Ogurtsova, Robert A Anders, Alexander H Fischer, Stefan Kraft, Meg R Gerstenblith, Cheryl L Thompson, Kord Honda, Jonathan D Cuda, Charles G Eberhart, James T Handa, Evan J Lipson & Janis M Taube. (2017) Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation 97:9, pages 1063-1071.
Crossref
Crossref
Markus V. Heppt, Lucie Heinzerling, Katharina C. K?hler, Andrea Forschner, Michael C. Kirchberger, Carmen Loquai, Markus Meissner, Friedegund Meier, Patrick Terheyden, Beatrice Schell, Rudolf Herbst, Daniela G?ppner, Felix Kiecker, David Rafei-Shamsabadi, Sebastian Haferkamp, Margit A. Huber, Jochen Utikal, Mirjana Ziemer, Irmgard Bumeder, Christiane Pfeiffer, Susanne G. Sch?d, Christoph Schmid-Tannwald, Julia K. Tietze, Thomas K. Eigentler & Carola Berking. (2017) Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. European Journal of Cancer 82, pages 56-65.
Crossref
Crossref
Kimberly M. Komatsubara & Richard D. Carvajal. (2017) Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Current Oncology Reports 19:7.
Crossref
Crossref
Katy K Tsai & Alain P Algazi. (2017) Are PD-1 antibodies safe for use in metastatic uveal melanoma?. Melanoma Management 4:2, pages 79-82.
Crossref
Crossref
Kimberly M. KomatsubaraJoanne JeterRichard D. CarvajalKim MargolinDirk SchadendorfAxel Hauschild. (2017) Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. American Society of Clinical Oncology Educational Book:37, pages 641-650.
Crossref
Crossref
Adriana Amaro, Rosaria Gangemi, Francesca Piaggio, Giovanna Angelini, Gaia Barisione, Silvano Ferrini & Ulrich Pfeffer. (2017) The biology of uveal melanoma. Cancer and Metastasis Reviews 36:1, pages 109-140.
Crossref
Crossref
Pui Ying Chan, Peter Hall, Gordon Hay, Victoria M. L. Cohen & Peter W. Szlosarek. (2017) A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell & Melanoma Research 30:6, pages 558-562.
Crossref
Crossref
Mario Sznol. (2017) Challenges in Conducting Clinical Research on Patients With Advanced Melanoma. The Cancer Journal 23:1, pages 75-78.
Crossref
Crossref
. (2016) Pembrolizumab. Reactions Weekly 1617:1, pages 188-188.
Crossref
Crossref